Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2020 - 2025)

Alnylam Pharmaceuticals (ALNY) has reported Long-Term Debt Issuances for 4 consecutive years, with -$680000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$680000.0; the trailing twelve-month figure through Dec 2025 stood at -$1.5 million (down 100.14% YoY), and the FY2025 full-year result was $645.7 million, changed N/A from the prior year.
• Long-Term Debt Issuances rose to -$680000.0 in Q4 2025 per ALNY's latest filing, from -$777000.0 in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $1.0 billion in Q3 2022 and bottomed at -$250.0 million in Q3 2021.
• Historically, Long-Term Debt Issuances has averaged $191.4 million across 3 years, with a median of -$728500.0 in 2022.
• The widest YoY moves for Long-Term Debt Issuances: up 506.76% in 2022, down 506.76% in 2022.
• Over 3 years, Long-Term Debt Issuances stood at -$250.0 million in 2021, then jumped by 99.69% to -$777000.0 in 2022, then increased by 12.48% to -$680000.0 in 2025.
• According to Business Quant data, Long-Term Debt Issuances over the past three periods registered -$680000.0, -$777000.0, and $1.0 billion for Q4 2025, Q4 2022, and Q3 2022 respectively.